Active substance
Results for the substance epcoritamab
2 results
About this active substance
Epcoritamab is an innovative medication used in the treatment of certain types of lymphoma, a form of cancer affecting the lymphatic system. This medicine belongs to the category of immuno-oncology therapies and works by stimulating the immune system to recognize and destroy cancer cells. Epcoritamab is usually administered by subcutaneous injection under close medical supervision.
Treatment with epcoritamab requires careful monitoring, as the response to therapy and any side effects must be closely observed. It is important for patients to follow the administration schedule and have regular tests to assess the effectiveness of the treatment.
Side effects may include fever, chills, fatigue, reactions at the injection site, or infections. In rare cases, severe immune reactions or a decrease in blood cell counts may occur, which is why constant medical supervision is necessary.
Epcoritamab is an important therapeutic option for patients with lymphoma, but its use must be strictly supervised by the medical team to ensure the safety and effectiveness of the treatment.
Treatment with epcoritamab requires careful monitoring, as the response to therapy and any side effects must be closely observed. It is important for patients to follow the administration schedule and have regular tests to assess the effectiveness of the treatment.
Side effects may include fever, chills, fatigue, reactions at the injection site, or infections. In rare cases, severe immune reactions or a decrease in blood cell counts may occur, which is why constant medical supervision is necessary.
Epcoritamab is an important therapeutic option for patients with lymphoma, but its use must be strictly supervised by the medical team to ensure the safety and effectiveness of the treatment.